Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03422094
Title Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

glioblastoma

Therapies

Ipilimumab + NeoVax + Nivolumab

NeoVax + Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.